VHTEAM > Feeds > Gusen pharmaceutical has obtained a new round of financing from Sequoia Capital and is a leading domestic R & D manufacturer of inhaler

Gusen pharmaceutical has obtained a new round of financing from Sequoia Capital and is a leading domestic R & D manufacturer of inhaler

2019-11-12 08:17:11Source: 36 krypton

Editor's note: This article comes from the WeChat public number "financial graffiti" (ID:caijingtuya), author & nbsp; Pang Shifan, editor Tuya, 36 krypton authorized release. According to financial graffiti, an intelligence expert of the company, Shanghai gusen Pharmaceutical Co., Ltd. has obtained a new round of financing, which is invested by Sequoia Capital in China. The specific amount has not been disclosed. In the case of gusen pharmaceutical, Sequoia capital subscribed rmb107635500 in the name of Sequoia Zhisheng investment partnership in Meishan free trade port, Ningbo, with a shareholding ratio of 12.5%, which is the second largest shareholder of the company. Gusen pharmaceutical was founded in 2017. With high-end preparations, especially the new generation of high-efficiency inhaler aerosol technology products as the core, it has combined the R & D platform resources of Peking University, Fudan University, Shanghai Institute of pharmaceutical science of Chinese Academy of Sciences and Shenyang Pharmaceutical University to produce pharmaceuticals, and established the "production, learning and research" ecological chain. The R & D team and R & D / industrialization base of the company are in the leading position in the industry. The high-end preparations, drug delivery technology, soft mist technology and products produced and developed by the company are far ahead in China, and the best inhalation soft mist agent

Tags: AR Qu AI
Publish information for free